No clear US plan on how COVID-19 antibody drugs will be distributed, paid for if approved

Maia Anderson –
Thursday, October 22nd, 2020
Print|Email.

The drug may be free at initially, as the federal government has supported advancement and production of Regenerons antibody drug and guaranteed to acquire the very first batch. But both drugs need to be given by IV infusion, which is pricey and must be done in a medical facility or specialized infusion center..

More posts on drug store:7 steps healthcare facilities, drugmakers are requiring to avoid COVID-19 vaccine thefts12 drugs being tested as COVID-19 treatmentsParticipant in AstraZenecas Brazil COVID-19 trial who passed away didnt get vaccine.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by clicking here.

As for allocation, Jewel Mullen, MD, the associate dean for health equity at the University of Texas Dell Medical School, informed NPR the drugs must be provided to healthcare workers and first responders initially, then to susceptible populations who stand to benefit the majority of..

Eli Lilly has said it will produce more than 1 million doses of its antibody drug prior to completion of the year. Regeneron has signed a $450 million handle the U.S. federal government to provide 300,00 dosages of its drug. With 50,000 Americans testing favorable for COVID-19 daily, demand will far outstrip supply, Rena Conti, PhD, an associate teacher of markets, public policy and law at Boston University, told NPR..

Read the full article here.

Both Regeneron and Eli Lilly have actually submitted emergency usage permission requests with the FDA for their COVID-19 antibody drugs, but there is no clear system for how the federal government will make sure the drugs will be designated fairly or how they will be spent for if they are approved, NPR reported..

Distribution of the drugs will be pricey. Dr. Conti said the drugs must be delivered in temperature-controlled trucks and have to get to rural areas dealing with COVID-19 break outs..

Even Medicare beneficiaries have copays for numerous infused drugs, NPR reported, and copays are usually 20 percent of the rate of a drug. The antibody drugs copays might be numerous dollars. Dr. Conti predicts the rate of the drugs to be $2,000 to $10,000 per treatment. If insurer pick up the expenses of the drugs, they would ultimately be passed along in premiums..

Eli Lilly has said it will produce more than 1 million doses of its antibody drug prior to the end of the year. Regeneron has actually signed a $450 million deal with the U.S. federal government to supply 300,00 doses of its drug. Even Medicare recipients have copays for numerous infused drugs, NPR reported, and copays are generally 20 percent of the rate of a drug. The antibody drugs copays could be hundreds of dollars.

Beckers has actually connected to HHS for comment and will update this story accordingly..